GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Shiller PE Ratio

Avalo Therapeutics (STU:C6K0) Shiller PE Ratio : (As of Jun. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Avalo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Shiller PE Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avalo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avalo Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Avalo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Shiller PE Ratio falls into.



Avalo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Avalo Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Avalo Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-129.72/131.7762*131.7762
=-129.720

Current CPI (Mar. 2024) = 131.7762.

Avalo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1,861.373 100.560 -2,439.199
201409 -2,820.015 100.428 -3,700.279
201412 5,052.287 99.070 6,720.230
201503 -1,861.638 99.621 -2,462.526
201506 -1,614.973 100.684 -2,113.694
201509 -205.525 100.392 -269.777
201512 -1,401.235 99.792 -1,850.336
201603 -1,525.882 100.470 -2,001.335
201606 -1,050.912 101.688 -1,361.862
201609 -1,796.256 101.861 -2,323.792
201612 -491.443 101.863 -635.763
201703 -511.632 102.862 -655.449
201706 -358.848 103.349 -457.552
201709 1,256.486 104.136 1,589.994
201712 -559.728 104.011 -709.144
201803 -280.282 105.290 -350.790
201806 -468.403 106.317 -580.570
201809 -1,752.394 106.507 -2,168.162
201812 -379.728 105.998 -472.076
201903 -331.344 107.251 -407.115
201906 -280.368 108.070 -341.871
201909 -183.053 108.329 -222.673
201912 77.760 108.420 94.511
202003 -886.176 108.902 -1,072.317
202006 -485.914 108.767 -588.705
202009 -415.670 109.815 -498.798
202012 -426.125 109.897 -510.962
202103 -774.144 111.754 -912.839
202106 -420.311 114.631 -483.175
202109 -424.320 115.734 -483.135
202112 -409.932 117.630 -459.232
202203 -512.112 121.301 -556.336
202206 -313.315 125.017 -330.255
202209 82.416 125.227 86.727
202212 -235.434 125.222 -247.757
202303 -190.536 127.348 -197.162
202306 -130.697 128.729 -133.791
202309 -24.737 129.860 -25.102
202312 -9.342 129.419 -9.512
202403 -129.720 131.776 -129.720

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avalo Therapeutics  (STU:C6K0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Avalo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics (STU:C6K0) Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Avalo Therapeutics (STU:C6K0) Headlines

No Headlines